Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts for Trastuzumab Cardiotoxicity: Results of the Cardiotoxicity of Adjuvant Trastuzumab Study

被引：0
|
作者：
Liu, J. [1 ]
Beith, J. [1 ]
Guo, Hao [2 ]
Barry, W. [2 ]
Bell, R. [3 ]
Murray, B. [1 ]
Lynch, J. [4 ,5 ]
Bastick, P. [4 ]
Chantrill, L. [6 ]
Kiely, B. E. [6 ]
Abdi, E. [7 ,8 ]
Rutovitz, J. [9 ]
Ashgari, R. [10 ]
Sullivan, A. [11 ]
Harrison, M. [1 ]
Kohonen-Corish, M. [12 ]
Goel, S. [2 ]
机构：
[1] Chris OBrien Lifehouse, Sydney, NSW, Australia
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Andrew Love Canc Ctr, Melbourne, Vic, Australia
[4] St George Hosp, Sydney, NSW, Australia
[5] Sutherland Hosp, Sydney, NSW, Australia
[6] Macarthur Canc Therapy Ctr, Sydney, NSW, Australia
[7] Tweed Hosp, Tweed Heads, Australia
[8] Griffith Univ, Nathan, Qld, Australia
[9] Northern Haematol & Oncol Grp, Sydney, NSW, Australia
[10] Bankstown Canc Ctr, Sydney, NSW, Australia
[11] Concord Repatriat Gen Hosp, Sydney, NSW, Australia
[12] Garvan Inst Med Res, Kinghorn Canc Ctr, Sydney, NSW, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：64 / 64
页数：1
相关论文
共 50 条
  • [41] Clinical utility of echocardiographic left-ventricular ejection fraction monitoring for cardiotoxicity risk assessment in patients with HER2+early breast cancer undergoing trastuzumab-based therapy
    Posch, F.
    Glantschnig, T.
    Firla, S.
    Smolle, M.
    Balic, M.
    Moik, F.
    Stoeger, H.
    Zirlik, A.
    Pichler, M.
    Rainer, P.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3844 - 3844
  • [42] Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
    Rea Levicki
    Martina Lovrić Benčić
    Irena Ivanac Vranešić
    Lada Bradić
    Marta Begovac
    Juraj Jug
    Natalija Dedić Plavetić
    The Egyptian Heart Journal, 75
  • [43] Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab
    Pistillucci, G.
    Ciorra, A. A.
    Sciacca, V.
    Raponi, M.
    Rossi, R.
    Veltri, E.
    CLINICA TERAPEUTICA, 2015, 166 (01): : E67 - E71
  • [44] Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
    Levicki, Rea
    Bencic, Martina Lovric
    Vranesic, Irena Ivanac
    Bradic, Lada
    Begovac, Marta
    Jug, Juraj
    Plavetic, Natalija Dedic
    EGYPTIAN HEART JOURNAL, 2023, 75 (01):
  • [45] Fluorouracil/trastuzumab/vinorelbineDecrease in left ventricular ejection fraction and acute pulmonary oedema: 3 case reports
    Reactions Weekly, 2017, 1658 (1) : 202 - 202
  • [46] From 60% to 5% in 12 Weeks: A Trastuzumab-Induced Left Ventricular Ejection Fraction Drop
    Pan, Qianjun
    Zhao, Rui
    Graham-Hill, Suzette
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [47] Trastuzumab-deruxtecanDecrease in left ventricular ejection fraction, pneumonitis and lack of efficacy : 3 case reports
    Reactions Weekly, 2023, 1958 (1) : 489 - 489
  • [48] Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: A real world population-based study
    Wadhwa, D.
    Fallah-Rad, N.
    Grenier, D.
    Krahn, M.
    Fang, T.
    Ahmadie, R.
    Lister, D.
    Arora, R. C.
    Barac, I.
    Morris, A.
    Jassal, D. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial
    Serie, Daniel J.
    Crook, Julia E.
    Necela, Brian M.
    Dockter, Travis J.
    Wang, Xue
    Asmann, Yan W.
    Fairweather, DeLisa
    Bruno, Katelyn A.
    Colon-Otero, Gerardo
    Perez, Edith A.
    Thompson, E. Aubrey
    Norton, Nadine
    PHARMACOGENETICS AND GENOMICS, 2017, 27 (10): : 378 - 385
  • [50] Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab
    Jacquinot, Quentin
    Paget-Bailly, Sophie
    Fumoleau, Pierre
    Romieu, Gilles
    Pierga, Jean Yves
    Espie, Marc
    Lortholary, Alain
    Nabholtz, Jean Marc
    Mercier, Celine Faure
    Pauporte, Iris
    Henriques, Julie
    Pivot, Xavier
    BREAST, 2018, 41 : 1 - 7
12345